One stock that might be an intriguing choice for investors right now is Cytori Therapeutics, Inc. (CYTX). This is because this security in the pharmaceutical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the pharmaceutical space as it currently has a Zacks Industry Rank of 60 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Cytori Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
In fact, over the past month, current quarter loss estimate has narrowed down from a loss of 10 cents a share to a loss of 8 cents per share, while current year loss estimate has narrowed down from a loss of 34 cents a share to a loss of 33 cents a share. This has helped CYTX to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.
So, if you are looking for a decent pick in a strong industry, consider Cytori Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CYTORI THERAPEU (CYTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research